1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research
Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options…
